Skip to main content

RenalytixAI Inks Deal to Introduce Kidney Function Testing Platform at University of Utah Health

NEW YORK — RenalytixAI has signed an agreement to roll out its KidneyIntelX kidney function testing platform at the University of Utah's academic medical center, the partners said on Wednesday.

KidneyIntelX, which was launched in September, uses machine learning algorithms to assess blood-based biomarkers and electronic health records to provide risk assessment of progressive decline in kidney function or kidney failure in patients with early-stage diabetic kidney disease.

Under the terms of the deal, the platform will be deployed into the electronic health record system at University of Utah Health, which serves millions of patients in Utah, Idaho, Wyoming, Montana, Colorado, and Nevada. Doing so is expected to improve test ordering and patient risk score reporting at the health system.

As part of the arrangement, RenalytixAI will provide financial support to the University of Utah over a five-year period in the form of sponsored research into kidney disease progression, treatment, and biomarkers, as well as software, education program development, and third-party resources.

Additional terms were not disclosed.

Last summer, UK-based RenalytixAI began working with AstraZeneca to use KidneyIntelX to improve outcomes for patients with chronic kidney disease and its complications.